We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

69 hedge funds and large institutions have $83.9M invested in OncoMed Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

19% more funds holding

Funds holding: 58 → 69 (+11)

10% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 20

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less capital invested

Capital invested by funds: $88.1M → $83.9M (-$4.14M)

Holders
69
Holders Change
+11
Holders Change %
+18.97%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
16
Increased
22
Reduced
20
Closed
5
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
-$70K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$18.6M
2
PA
Perceptive Advisors
New York
+$6.89M
3
Millennium Management
Millennium Management
New York
+$1.41M
4
CM
Crestline Management
Texas
+$799K
5
ECM
Endurant Capital Management
California
+$605K

Top Sellers

Rank Fund Capital Flow
1
ASP
Adams Street Partners
Illinois
-$4.27M
2
BlackRock
BlackRock
New York
-$2.47M
3
IHM
Iguana Healthcare Management
New York
-$870K
4
CS
Candriam SCA
Luxembourg
-$218K
5
PP
PDT Partners
New York
-$147K
Name Holding Trade Value Shares
Change 		Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
26
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$248K -$41K -9,425 -13%
PP
27
PDT Partners
New York
$242K -$147K -33,800 -36%
Northern Trust
28
Northern Trust
Illinois
$242K -$29.5K -6,782 -10%
SIM
29
Spark Investment Management
New York
$228K +$243K +55,800 New
Charles Schwab
30
Charles Schwab
California
$226K +$19K +4,368 +9%
Squarepoint
31
Squarepoint
New York
$222K +$136K +31,191 +136%
Goldman Sachs
32
Goldman Sachs
New York
$214K +$107K +24,653 +90%
Jacobs Levy Equity Management
33
Jacobs Levy Equity Management
New Jersey
$198K +$28.7K +6,600 +16%
Citadel Advisors
34
Citadel Advisors
Florida
$183K +$47.8K +10,991 +33%
VF
35
Virtu Financial
New York
$170K +$180K +41,395 New
Tudor Investment Corp
36
Tudor Investment Corp
Connecticut
$167K +$38.1K +8,746 +27%
NSEDCP
37
NJ State Employees Deferred Compensation Plan
New Jersey
$156K – – –
PP
38
Paloma Partners
Connecticut
$135K +$143K +32,858 New
OAM
39
Oxford Asset Management
United Kingdom
$135K +$143K +32,910 New
BCM
40
BlueCrest Capital Management
Jersey
$133K +$141K +32,382 New
Barclays
41
Barclays
United Kingdom
$121K +$121K +27,792 +1,488%
BC
42
Birchview Capital
Vermont
$118K – – –
Wells Fargo
43
Wells Fargo
California
$118K +$105K +24,196 +539%
Bank of New York Mellon
44
Bank of New York Mellon
New York
$117K +$22.5K +5,169 +22%
ARTA
45
A.R.T. Advisors
New York
$110K +$118K +27,052 New
ZIM
46
Zacks Investment Management
Illinois
$89K -$10.4K -2,400 -10%
State Street
47
State Street
Massachusetts
$85K +$32.9K +7,567 +58%
KAM
48
Kazazian Asset Management
Florida
$80K +$84.9K +19,512 New
AGM
49
Alpine Global Management
New York
$77K +$81.4K +18,701 New
HCM
50
Hodges Capital Management
Texas
$64K -$43.5K -10,000 -39%
1
2
3

OMED Hedge Fund Activity: Q4 2017 in Review

69 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q4 2017, worth a combined $83.9M — down 4.7% from $88.1M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new OMED positions and 5 closed out — a net gain of 11 holders — while 22 added to existing stakes and 20 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $18.6M. The largest seller was Adams Street Partners, cutting an estimated $4.27M.

  • 69 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q4 2017, up from 58 in Q3 2017.
  • Funds reported $83.9M of OncoMed Pharmaceuticals, Inc. stock for Q4 2017, down 4.7% quarter-over-quarter.
  • 16 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q4 2017 and 5 closed out, a net change of +11 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q4 2017 was BVF Inc, an estimated $18.6M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q4 2017 was Adams Street Partners, an estimated $4.27M sold.

Based on aggregated 13F filings for Q4 2017.